Almiba solution for oral administration in vials 10ml №10

Almiba Oral Solution: 100mg/ml, 10ml Vials (Pack of 10) – Treat Levocarnitine Deficiency

Description:

Almiba Oral Solution is a clear, colorless to pale yellow liquid containing Levocarnitine, an essential nutrient for energy production and muscle function. This convenient 100mg/ml solution is packaged in 10ml vials, offering a convenient and effective way to manage levocarnitine deficiency in adults and children.

Indications:

Almiba is indicated for the treatment of primary and secondary levocarnitine deficiency in patients of all ages, including:

• Primary Levocarnitine Deficiency: A rare genetic disorder where the body cannot properly absorb or utilize levocarnitine.
• Secondary Levocarnitine Deficiency: Occurs in various conditions, including:
  • End-stage kidney disease: Patients on long-term hemodialysis often experience levocarnitine deficiency, leading to muscle cramps, weakness, and other complications.
  • Malnutrition: Lack of sufficient dietary levocarnitine can lead to deficiency.

Dosage and Administration:

Almiba Oral Solution is intended for oral use only. It should be diluted with water or juice before administration and taken before meals. The dosage varies based on age, weight, and the severity of the condition.

Dosage Table:

Important Notes:

• For children under one year, dosage should be calculated based on body weight.
• If clinical and biochemical improvement is not observed, a short-term dose increase may be considered.
• In severe cases of acute metabolic decompensation, doses up to 400mg/kg/day may be necessary.

Use During Pregnancy and Lactation:

• Studies have shown no teratogenic effects of levocarnitine, but limited data is available on its use in pregnant women with primary carnitine deficiency.
• Levocarnitine is a normal component of human milk, but its effects on breastfeeding mothers have not been studied.
• Consult your doctor to weigh the risks and benefits of levocarnitine treatment during pregnancy and lactation.

Precautions:

• Diabetes: Almiba may increase hypoglycemia in diabetic patients taking insulin or oral hypoglycemic agents. Regular glucose monitoring and adjustments to hypoglycemic therapy may be required.
• Renal Impairment: The safety and efficacy of oral levocarnitine in patients with renal insufficiency are not fully established.
• Long-term High-Dose Use: Long-term administration of high doses of oral levocarnitine in patients with renal impairment or end-stage renal disease on hemodialysis may lead to the accumulation of toxic metabolites.

Contraindications:

• Hypersensitivity to levocarnitine or any of the drug’s components.

Composition:

• 1 ml of Almiba Oral Solution contains 100 mg of levocarnitine.
• Excipients: Malic acid, sodium methylparaben E219, sodium propylparaben E217, sodium saccharin dihydrate, cherry flavor (propylene glycol, citric acid, water), water for injection.

Overdose:

There is no information on the toxicity of levocarnitine overdose. In case of overdose, general supportive measures should be taken.

Side Effects:

Long-term use of oral levocarnitine may cause mild gastrointestinal disorders such as nausea, vomiting, abdominal cramps, and diarrhea. Moderate myasthenia gravis has been reported in uremic patients treated with levocarnitine. Reducing the dosage may alleviate these symptoms.

Storage:

Store Almiba Oral Solution below 25°C, protected from light, and out of reach of children.

Buy Almiba Oral Solution:

Find Almiba Oral Solution in 10ml vials (pack of 10) at [insert link to pharmacy or online retailer].

Disclaimer:

This information is for general knowledge purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional for personalized medical guidance and treatment.